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 Temocillin is a β-lactam increasingly used in serious infections caused by 
Enterobacteriaceae, including ESBLs and even some carbapenemase-producing 
strains, as an alternative to carbapenems, especially in critically ill patients (1-5) . 
 Temocillin is licensed in UK, France, and Belgium for lower respiratory tract 
infections although clinical data are scarce and no data about Epithelial Lining 
Fluid (ELF) concentrations are available.  
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 10 adult patients with severe bacteriologically documented nosocomial pneumonia 
occuring in ICU were prospectively enrolled and received CI of 6g/day of temocillin 
after a 30-min 2g loading dose.  
 Plasma and ELF samples were obtained at steady-state and total and free 
concentrations of temocillin were measured by UHPLC-MS/MS method. 
Concerning the determination of free temocillin concentrations, an 
ultracentrifugation prior to UHPLC-MS/MS method was performed (6) .  
 Timing of serial plasma and unique ELF samplings (n = 10) per patient was as 
follow: 
 The administration of 6g per day of temocillin by continuous infusion in critically patients with severe nosocomial pneumonia allows a 
penetration ratio, measured by the ELF/plasma ratio of AUCs, of 0.14 and 0.57 and a mean (± SE) ELF concentration , in mg/L, of 9.8 
± 1.3  and 9.8 ± 1.6 for total and free drug, respectively. Standard error of AUCs should be calculated by the Bootstrap method and 
Monte Carlo simulations should be performed for subsequent PK/PD analysis. 
  Plasma  
(mean ± SE) 
ELF  
(mean ± SE) 
ELF/plasma ratio 
(mean ± SE) 
Total temocillin concentration 
(mg/L) 
68.0 ± 11.3 9.8 ± 1.3 0.17 ± 0.03 
Free temocillin concentration 
(mg/L) 
17.3 ± 4.8 9.8 ± 1.6 0.84 ± 0.18  
  
  Plasma ELF ELF/plasma ratio 
AUC0-24 
(mg.h/L) 
Total temocillin 1632  235  0.14  
Free temocillin 415 235 0.57  
Conclusions 
Background 
We aim to determine serum and ELF temocillin concentrations administered by 
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Figure 1.  
(●) ELF concentrations: one sample per patient 
(─) Plasma concentrations: three samples per patient  
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 A high pharmacokinetic interindividual variability was observed in plasma and 
ELF for both total and free concentrations but these concentrations remained 




 Samplings were performed at mean (± SD) 33.2 ± 22.8 hours after the start of CI. 
 The mean (± SD) creatinine clearance based on 24h urine was 112.2 ± 40.7 ml/min/1.73m2, including 3 patients with value 
> 120 ml/min/1.73 m2 and 1 patient receiving CVVH. 
 Total and free temocillin concentrations and AUC in both plasma and ELF and their respective ELF/plasma ratios are 
presented in Table 1. 
